<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261387</url>
  </required_header>
  <id_info>
    <org_study_id>LUT-RD-02-01</org_study_id>
    <nct_id>NCT04261387</nct_id>
  </id_info>
  <brief_title>LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients</brief_title>
  <official_title>A Phase I/II, Open-label Study, Evaluating the Safety, Tolerability and Efficacy of Topically Administered LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lutris Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lutris Pharma Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically
      administered in breast cancer patients who developed radiation dermatitis.

      Eligible subjects will be enrolled to receive the study treatment for 28 days and will be
      followed up for 2 months after the completion of study treatment
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Common Terminology Criteria for Adverse Events Version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the severity of radiation dermatitis assessed by CTCAE</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>CTCAE grading scale for dermatitis radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the severity of radiation dermatitis assessed by RTOG/EORTC</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire</measure>
    <time_frame>12 weeks (83 days)</time_frame>
    <description>Dermatology Life Quality Index questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>LUT014 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUT014 Gel topical application to the dermatitis area qd for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUT014 Gel</intervention_name>
    <description>Topical application qd for 28 days</description>
    <arm_group_label>LUT014 Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer;

          2. Subject is ≥18 years at the time of signing the informed consent form (ICF);

          3. Radiation dermatitis of Grade ≥ 1, based on the NCI CTCAE at the Screening and
             Baseline (D0) visits;

          4. Subject is currently on radiation therapy regimen or completed the radiation within 14
             days prior to screening

          5. A score of ≥ 6 reported in the Dermatology Life Quality Index at the Screening Visit;

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          7. Females of child-bearing potential must have a negative pregnancy test at screening
             and must agree to use an effective contraception method* or abstain from sex
             throughout the study until Day 55;

          8. Expected life expectancy greater than 6 months

        Exclusion Criteria:

          1. Subject is planned to receive Internal Mammary Node irradiation with electrons.
             (Photon coverage of internal mammary chain nodes is acceptable for inclusion in the
             study);

          2. Any cutaneous infection or skin disease in the area to be irradiated;

          3. T4 tumors or direct skin involvement by tumor;

          4. Partial breast accelerated irradiation is planned;

          5. Irradiation to bilateral breasts;

          6. Breast implants or subjects who undergone breast reconstruction;

          7. Subject is scheduled to receive concurrent chemotherapy [Subjects may receive
             concurrent hormonal therapy or be on Herceptin® (Trastuzumab) while on the study];

          8. Treatment with topical corticosteroids or any other topical medication including
             over-the counter medications, applied to treatment area within 14 days prior to
             Screening;

          9. Any cancer other than Breast Cancer within 3 years of Screening, except for carcinoma
             in situ of the cervix;

         10. Pregnant or lactating;

         11. Subject has a history of active systemic lupus erythematosus or scleroderma that is
             believed to increase the risk of radiation dermatitis development and its severity;

         12. Clinically significant co-morbid diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Assuta Ashdod</name>
      <address>
        <city>Ashdod</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Eli Sapir, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

